IllExcor Therapeutics LLC
Oral small-molecule anti-sickling drugs based on aromatic aldehydes that stabilize hemoglobin and prevent red blood cell polymerization
- Sector
- Biotech
- Headquarters
- Richmond, VA
- Founded
- 2026
- Latest Form D
- $13M, May 2026
- Total capital
- $20.2M
- Federal grants
- $7.2M
- 12 awards · 2020–2025
- Rank in peer group#155 of 326
- Private capital raised
- $13M
- 1 Form D · last May 2026
- 6 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 1 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$13M
- Federal grantHealth and Human S · Phase II · Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$529K
- Federal grantHealth and Human S · Phase II · Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$798K
- Federal grantHealth and Human S · Phase II · Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$888K
- Federal grantHealth and Human S · Phase II · Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$808K
- Federal grantHealth and Human S · Phase II · Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$977K
- Federal grantHealth and Human S · Phase II · Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$977K
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$746K
- Federal grantHealth and Human S · Phase I · Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$298K
- Federal grantHealth and Human S · Phase I · Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$300K
- Federal grantHealth and Human S · Phase I · Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$300K
- Federal grantHealth and Human S · Phase I · Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease$300K
- Federal grantHealth and Human S · Phase I · Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
75months
from IllExcor Therapeutics LLC’s first federal award to its first private round.
- First federal award · Feb 2020
- Health and Human S · $300K
- First Form D · May 2026
- $13M · 1st Form D
- Awards before first raise
- 12 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#155 · top 48%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Andrew N FleischmanExecutive Officer, DirectorNamed in SEC Form D filings
- Giovanni E MariggiDirectorNamed in SEC Form D filings
- Maneka E MirchandaneyDirectorNamed in SEC Form D filings
- Ted E LoveDirectorNamed in SEC Form D filings
- Timothy E LadinExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 1- PendingBenzaldehyde Compounds With Direct Polymer Destabilizing Effects To Treat Sickle Cell DiseaseUSPTOApplication 18501244
Related companies, and why
- NOVORON BIOSCIENCE INCSimilar federal contract value in Biotech · null in contracts
- ADAPTIN BIO, INC.Similar federal contract value in Biotech · null in contracts
- Tolera Therapeutics IncSimilar federal contract value in Biotech · null in contracts
- InMed Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Sunstone Therapies, Inc.Similar federal contract value in Biotech · null in contracts
- EvodiaBioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .